Last checked at 16 Aug 2018 07:00
hVIVO plc
("hVIVO" or the "Company")
Notice of Interim Results
London, UK, 16 August 2018: hVIVO plc (AIM: HVO), a pioneer of human disease models and an industry leading clinical development services business, will announce its interim financial results for the six months ended 30 June 2018 on Thursday 20 September 2018.
A presentation and webcast for analysts will be held at 9.00am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 8.45am. A webcast recording of the event will be available on the Company's website.
For further information please contact:
hVIVO plc |
|
Trevor Phillips (Executive Chairman) | +44 207 756 1300 |
Graham Yeatman (Chief Financial Officer) Fleur Wood (Director, Investor Relations)
|
|
Numis Securities Limited | +44 207 260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser) |
|
James Black / Michael Burke (Corporate Broking) |
|
|
|
FTI Consulting |
|
Simon Conway / Victoria Foster Mitchell | +44 203 727 1000 |
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based analytical platform to accelerate drug discovery and development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV and asthma exacerbation, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies, inoculated over 2500 volunteers and has three first-in-class therapies currently in development.